Orphan drugs for myelofibrosis

Bibliography

• Dameshek W. Some speculations on the myeloproliferative syndromes. Blood 1951;6:372-5
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 2008
   Google Scholar
• Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054-61
   PubMed Web of Science ®Google Scholar
• James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144-8
   PubMed Web of Science ®Google Scholar
• Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:1779-90
   PubMed Web of Science ®Google Scholar
• Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7:387-97
   PubMed Web of Science ®Google Scholar
• Dawson MA, Bannister AJ, Gottgens B, et al. JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin. Nature 2009;461:819-22
   PubMed Web of Science ®Google Scholar
• Pikman Y, Lee BH, Mercher T, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006;3:e270
   PubMed Web of Science ®Google Scholar
• Gisslinger H, Harutyunyan AS, Nivarthi H, et al. Frequent mutations in the calreticulin gene CALR in myeloproliferative neoplasms. Blood 2013;122:LBA-1
   Web of Science ®Google Scholar
• Massie C, Baxter EJ, Nice FL, et al. The genomic landscape of myeloproliferative neoplasms: somatic Calr mutations in the majority of JAK2-wildtype patients. Blood 2013;122:LBA-2
   Web of Science ®Google Scholar
• Biamonte F, Pieri L, Rotunno G, et al. Impact of prognostically detrimental mutations (ASXL1, EZH2, SRSF2, IDH1/2) on outcomes in patients with myelofibrosis treated with ruxolitinib in COMFORT-II. Blood 2013;122:107
   Web of Science ®Google Scholar
• Vannucchi AM, Lasho TL, Guglielmelli P, et al. Mutations and prognosis in primary myelofibrosis. Leukemia 2013;27:1861-9
   PubMed Web of Science ®Google Scholar
• Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009;113:2895-901
   PubMed Web of Science ®Google Scholar
• Mesa RA, Li CY, Ketterling RP, et al. Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood 2005;105:973-7
   PubMed Web of Science ®Google Scholar
• Cervantes F, Tassies D, Salgado C, et al. Acute transformation in nonleukemic chronic myeloproliferative disorders: actuarial probability and main characteristics in a series of 218 patients. Acta Haematol 1991;85:124-7
   PubMed Web of Science ®Google Scholar
• Gangat N, Caramazza D, Vaidya R, et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 2011;29:392-7
   PubMed Web of Science ®Google Scholar
• Ballen K. How to manage the transplant question in myelofibrosis. Blood Cancer J 2012;2:e59
   PubMed Web of Science ®Google Scholar
• Barbui T, Barosi G, Birgegard G, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 2011;29:761-70
   PubMed Web of Science ®Google Scholar
• Ianotto JC, Boyer-Perrard F, Gyan E, et al. Efficacy and safety of pegylated-interferon alpha-2a in myelofibrosis: a study by the FIM and GEM French cooperative groups. Br J Haematol 2013;162(6):783-91
   PubMed Web of Science ®Google Scholar
• Tefferi A, Elliot MA, Yoon SY, et al. Clinical and bone marrow effects of interferon alfa therapy in myelofibrosis with myeloid metaplasia. Blood 2001;97:1896
   PubMed Web of Science ®Google Scholar
• Kennedy BJ. Effect of androgenic hormone in myelofibrosis. JAMA 1962;182:116-19
   PubMed Web of Science ®Google Scholar
• Brubaker LH, Briere J, Laszlo J, et al. Treatment of anemia in myeloproliferative disorders: a randomized study of fluoxymesterone v transfusions only. Arch Intern Med 1982;142:1533-7
   PubMedGoogle Scholar
• Cervantes F, Alvarez-Larran A, Domingo A, et al. Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: long-term results in 30 patients. Br J Haematol 2005;129:771-5
   PubMed Web of Science ®Google Scholar
• Cervantes F, Alvarez-Larran A, Hernandez-Boluda JC, et al. Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature. Br J Haematol 2004;127:399-403
   PubMed Web of Science ®Google Scholar
• Huang J, Tefferi A. Erythropoiesis stimulating agents have limited therapeutic activity in transfusion-dependent patients with primary myelofibrosis regardless of serum erythropoietin level. Eur J Haematol 2009;83:154-5
   PubMed Web of Science ®Google Scholar
• Iki S, Yagisawa M, Ohbayashi Y, et al. Adverse effect of erythropoietin in myeloproliferative disorders. Lancet 1991;337:187-8
   PubMed Web of Science ®Google Scholar
• Sato T, Wakabayashi Y, Nishikawa T, et al. [Rapid aggravation of splenomegaly by administration of erythropoietin in a case of myelodysplastic syndrome]. Rinsho Ketsueki 1992;33:1857-62
   PubMedGoogle Scholar
• Tabarroki A, Tiu RV. Immunomodulatory agents in myelofibrosis. Expert Opin Investig Drugs 2012;21:1141-54
   PubMed Web of Science ®Google Scholar
• Jabbour E, Thomas D, Kantarjian H, et al. Comparison of thalidomide and lenalidomide as therapy for myelofibrosis. Blood 2011;118:899-902
   PubMed Web of Science ®Google Scholar
• Tefferi A, Lasho TL, Mesa RA, et al. Lenalidomide therapy in del(5)(q31)-associated myelofibrosis: cytogenetic and JAK2V617F molecular remissions. Leukemia 2007;21:1827-8
   PubMed Web of Science ®Google Scholar
• Takahashi K, Cortes J, Pierce S, et al. Chromosome 5q deletion is extremely rare in patients with myelofibrosis. Leuk Res 2013;37:552-5
   PubMed Web of Science ®Google Scholar
• Tefferi A, Verstovsek S, Barosi G, et al. Pomalidomide is active in the treatment of anemia associated with myelofibrosis. J Clin Oncol 2009;27:4563-9
   PubMed Web of Science ®Google Scholar
• Daver N, Shastri A, Kadia T, et al. Modest activity of pomalidomide in patients with myelofibrosis and significant anemia. Leuk Res 2013;37(11):1440-4
   PubMed Web of Science ®Google Scholar
• Mesa RA, Pardanani AD, Hussein K, et al. Phase1/-2 study of Pomalidomide in myelofibrosis. Am J Hematol 2010;85:129-30
   PubMed Web of Science ®Google Scholar
• Passamonti F, Barbui T, Barosi G, et al. Phase 3 study of pomalidomide in myeloproliferative neoplasm (MPN)-associated myelofibrosis with RBC-transfusion-dependence. Blood 2013;122:394
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Fenaux P, Sekeres MA, et al. Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. J Clin Oncol 2010;28:437-44
   PubMed Web of Science ®Google Scholar
• Ghanima W, Junker P, Hasselbalch HC, et al. Fibroproliferative activity in patients with immune thrombocytopenia (ITP) treated with thrombopoietic agents. Br J Haematol 2011;155:248-55
   PubMed Web of Science ®Google Scholar
• Giagounidis A, Mufti GJ, Kantarjian HM, et al. Treatment with the thrombopoietin (TPO)-receptor agonist romiplostim in thrombocytopenic patients (Pts) with low or intermediate-1 (Int-1) risk myelodysplastic syndrome (MDS): results of a randomized, double-blind, placebo(PBO)-controlled study. ASH Annual Meeting Abstr 2011;118:117
   Google Scholar
• Kantarjian HM, Mufti GJ, Fenaux P, et al. Treatment with the thrombopoietin (TPO)-receptor agonist romiplostim in thrombocytopenic patients (Pts) with low or intermediate-1 (int-1) risk myelodysplastic syndrome (MDS): follow-up AML and survival results of a randomized, double-blind, placebo (PBO)-controlled study. ASH Annu Meeting Abstr 2012;120:421
   Google Scholar
• Martinez-Trillos A, Gaya A, Maffioli M, et al. Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients. Ann Hematol 2010;89:1233-7
   PubMed Web of Science ®Google Scholar
• Ianotto JC, Boyer-Perrard F, Gyan E, et al. Efficacy and safety of pegylated-interferon alpha-2a in myelofibrosis: a study by the FIM and GEM French cooperative groups. Br J Haematol 2013;162(6):783-91
   PubMed Web of Science ®Google Scholar
• Santos FP, Tam CS, Kantarjian H, et al. Splenectomy in patients with myeloproliferative neoplasms: efficacy, complications and impact on survival and transformation. Leuk Lymphoma 2014;55(1):121-7
   PubMed Web of Science ®Google Scholar
• Elliott MA, Chen MG, Silverstein MN, Tefferi A. Splenic irradiation for symptomatic splenomegaly associated with myelofibrosis with myeloid metaplasia. Br J Haematol 1998;103:505-11
   PubMed Web of Science ®Google Scholar
• Bouabdallah R, Coso D, Gonzague-Casabianca L, et al. Safety and efficacy of splenic irradiation in the treatment of patients with idiopathic myelofibrosis: a report on 15 patients. Leuk Res 2000;24:491-5
   PubMed Web of Science ®Google Scholar
• Ito T, Akagi K, Kondo T, et al. Splenic irradiation as a component of a reduced-intensity conditioning regimen for hematopoietic stem cell transplantation in myelofibrosis with massive splenomegaly. Tohoku J Exp Med 2012;228:295-9
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Vaddi K, Liu P, et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 2010;115:3109-17
   PubMed Web of Science ®Google Scholar
• Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012;366:787-98
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012;366:799-807
   PubMed Web of Science ®Google Scholar
• Cervantes F, Vannucchi AM, Kiladjian JJ, et al. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood 2013;122:4047-53
   PubMed Web of Science ®Google Scholar
• Talpaz M, Paquette R, Afrin L, et al. Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts. J Hematol Oncol 2013;6:81
   PubMed Web of Science ®Google Scholar
• Kvasnicka HM, Thiele J, Bueso-Ramos C, et al. Long-term intervention effects on bone marrow morphology in myelofibrosis: Patients treated with ruxolitinib and best available therapy [abstract s591]. Haematologia (Budap) 2013;98(s1):249
   Google Scholar
• Wilkins BS, Radia D, Woodley C, et al. Resolution of bone marrow fibrosis in a patient receiving JAK1/JAK2 inhibitortreatment with ruxolitinib. Haematologica 2013;98(12):1872-6
   PubMed Web of Science ®Google Scholar
• Vannucchi A, Kiladjian JJ, Gisslinger H, et al. Reductions in JAK2V617F allele burden with ruxolitinib treatment in COMFORT-II, a phase 3 study comparing the safety and efficacy of ruxolitinib to best available therapy (BAT) [abstract 0373]. Haematologia (Budap) 2012;97(s1):151
   Google Scholar
• Gotlib J, Maxson JE, George TI, Tyner JW. The new genetics of chronic neutrophilic leukemia and atypical CML: implications for diagnosis and treatment. Blood 2013;122:1707-11
   PubMed Web of Science ®Google Scholar
• Wernig G, Kharas MG, Okabe R, et al. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell 2008;13:311-20
   PubMed Web of Science ®Google Scholar
• Talpaz M, Jamieson C, Gabrail N, et al. Updated results from a randomized phase 2 dose-ranging study of the JAK2-selective inhibitor SAR302503 in patients with intermediate-2 or high-risk myelofibrosis (MF) [abstract S1113]. Haematologia (Budap) 2013;98(s1):458
   Google Scholar
• Talpaz M, Jamieson C, Gabrail N, et al. Modulation of plasma cytokines and its association with clinical response to treatment with the JAK2-selective inhibitor SAR302503 in a phase 2 study of patients with myelofibrosis (MF) [abstract p272]. Haematologia (Budap) 2013;98(s1):117
   Google Scholar
• Harrison CN, Cortes JE, Cervantes F, et al. Results of a randomized, double-blind, placebo-controlled phase III study (JAKARTA) of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis (MF). Blood 2013;122:393
   Web of Science ®Google Scholar
• Schaap NP, Zweegman S, Jourdan E, et al. Efficacy and safety of fedratinib (SAR302503/TG101348) in patients with intermediate- or high-risk myelofibrosis (MF), post-polycythemia vera (PV) MF, or post-essential thrombocythemia (ET) MF previously treated with ruxolitinib: interim results from a phase II study (JAKARTA-2). Blood 2013;122:661
   Web of Science ®Google Scholar
• Pardanani A, Lasho T, Smith G, et al. CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients. Leukemia 2009;23:1441-5
   PubMed Web of Science ®Google Scholar
• Pardanani A, Laborde RR, Lasho TL, et al. Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis. Leukemia 2013;27:1322-7
   PubMed Web of Science ®Google Scholar
• Gotlib J, Gupta V, Roberts AW, et al. Update on the long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis. Blood 2013;122:108
   Web of Science ®Google Scholar
• William AD, Lee AC, Blanchard S, et al. Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6). 1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphoma. J Med Chem 2011;54:4638-58
   PubMed Web of Science ®Google Scholar
• Komrokji R, Wadleigh M, Seymour J, et al. Results of a phase 2 study of pacritinib (SB 1518), a novel oral JAK2 inhibitor, in patients with primary, post-polycythemia vera, and posy-essential thrombocythemia myelofibrosis. Blood 2011;118:abstract 282
   Web of Science ®Google Scholar
• Levis M, Ravandi F, Wang ES, et al. Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood 2011;117:3294-301
   PubMed Web of Science ®Google Scholar
• Hexner EO, Serdikoff C, Jan M, et al. Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders. Blood 2008;111:5663-71
   PubMed Web of Science ®Google Scholar
• Santos FP, Kantarjian HM, Jain N, et al. Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood 2010;115:1131-6
   PubMed Web of Science ®Google Scholar
• Hedvat M, Huszar D, Herrmann A, et al. The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell 2009;16:487-97
   PubMed Web of Science ®Google Scholar
• Ioannidis S, Lamb ML, Wang T, et al. Discovery of 5-chloro-N2-[(1S)-1-(5-fluoropyrimidin-2-yl)ethyl]-N4-(5-methyl-1H-pyrazol-3-yl)p yrimidine-2,4-diamine (AZD1480) as a novel inhibitor of the Jak/Stat pathway. J Med Chem 2011;54:262-76
   PubMed Web of Science ®Google Scholar
• Scuto A, Krejci P, Popplewell L, et al. The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival. Leukemia 2011;25:538-50
   PubMed Web of Science ®Google Scholar
• Purandare AV, McDevitt TM, Wan H, et al. Characterization of BMS-911543, a functionally selective small-molecule inhibitor of JAK2. Leukemia 2012;26:280-8
   PubMed Web of Science ®Google Scholar
• Roberts AW, Seymour JF, Burbury K, et al. BMS-911543, a selective JAK2 inhibitor: a multicenter phase 1/2a study in myelofibrosis. Blood 2013;122:664
   Web of Science ®Google Scholar
• Nakaya Y, Shide K, Niwa T, et al. Efficacy of NS-018, a potent and selective JAK2/Src inhibitor, in primary cells and mouse models of myeloproliferative neoplasms. Blood Cancer J 2011;1:e29
   PubMed Web of Science ®Google Scholar
• Changelian PS, Flanagan ME, Ball DJ, et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 2003;302:875-8
   PubMed Web of Science ®Google Scholar
• Manshouri T, Quintas-Cardama A, Nussenzveig RH, et al. The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation. Cancer Sci 2008;99:1265-73
   PubMed Web of Science ®Google Scholar
• Ma L, Clayton JR, Walgren RA, et al. Discovery and characterization of LY2784544, a small-molecule tyrosine kinase inhibitor of JAK2V617F. Blood Cancer J 2013;3:e109
   PubMed Web of Science ®Google Scholar
• Mesa RA, Salama ME, Giles JLK, et al. Phase I study of LY2784544, a JAK2 selective inhibitor, in patients with myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). Blood 2013;122:665
   Web of Science ®Google Scholar
• Shah NP, Olszynski P, Sokol L, et al. A phase I study of XL019, a selective JAK2 inhibitor, in patients with primary myelofibrosis, post-polycythemia vera, or post-essential thrombocythemia myelofibrosis. ASH Annu Meeting Abstr 2008;112:98
   Google Scholar
• Quintas-Cardama A, Kantarjian H, Cortes J, Verstovsek S. Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. Nat Rev Drug Discov 2011;10:127-40
   PubMed Web of Science ®Google Scholar
• Talpaz M, Gupta V, Savona M, et al. An open-label, phase II study of the JAK1 inhibitor INCB039110 in patients with myelofibrosis. Blood 2013;122:663
   Google Scholar
• Owonikoko TK, Khuri FR. Targeting the PI3K/AKT/mTOR pathway. Am Soc Clin Oncol Educ Book 2013;2013:395-401
   Google Scholar
• Ugo V, Marzac C, Teyssandier I, et al. Multiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia vera. Exp Hematol 2004;32:179-87
   PubMed Web of Science ®Google Scholar
• Laubach JP, Fu P, Jiang X, et al. Polycythemia vera erythroid precursors exhibit increased proliferation and apoptosis resistance associated with abnormal RAS and PI3K pathway activation. Exp Hematol 2009;37:1411-22
   PubMed Web of Science ®Google Scholar
• Grimwade LF, Happerfield L, Tristram C, et al. Phospho-STAT5 and phospho-Akt expression in chronic myeloproliferative neoplasms. Br J Haematol 2009;147:495-506
   PubMed Web of Science ®Google Scholar
• Maira SM, Stauffer F, Brueggen J, et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 2008;7:1851-63
   PubMed Web of Science ®Google Scholar
• Chapuis N, Tamburini J, Green AS, et al. Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia. Clin Cancer Res 2010;16:5424-35
   PubMed Web of Science ®Google Scholar
• Fiskus W, Verstovsek S, Manshouri T, et al. Dual PI3K/AKT/mTOR inhibitor BEZ235 synergistically enhances the activity of JAK2 inhibitor against cultured and primary human myeloproliferative neoplasm cells. Mol Cancer Ther 2013;12:577-88
   PubMed Web of Science ®Google Scholar
• Ansbro MF, Shukla S, Ambudkar SV, et al. Screening compounds with a novel high-throughput ABCB1-mediated efflux assay identifies drugs with known therapeutic targets at risk for multidrug resistance interference. PLoS One 2013;8(4):e60334
   PubMed Web of Science ®Google Scholar
• Maira SM, Pecchi S, Huang A, et al. Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor. Mol Cancer Ther 2012;11:317-28
   PubMed Web of Science ®Google Scholar
• Zheng Y, Yang J, Qian J, et al. Novel phosphatidylinositol 3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma cells and shows synergistic anti-myeloma activity with dexamethasone. J Mol Med (Berl) 2012;90:695-706
   PubMed Web of Science ®Google Scholar
• Geisthoff UW, Nguyen HL, Hess D. Improvement in hereditary hemorrhagic telangiectasia after treatment with the phosphoinositide 3-kinase inhibitor BKM120. Ann Hematol 2013. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Hirai H, Sootome H, Nakatsuru Y, et al. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther 2010;9:1956-67
   PubMed Web of Science ®Google Scholar
• Khan I, Huang Z, Wen Q, et al. AKT is a therapeutic target in myeloproliferative neoplasms. Leukemia 2013;27(9):1882-90
   PubMed Web of Science ®Google Scholar
• Schuler W, Sedrani R, Cottens S, et al. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation 1997;64:36-42
   PubMed Web of Science ®Google Scholar
• Albert S, Serova M, Dreyer C, et al. New inhibitors of the mammalian target of rapamycin signaling pathway for cancer. Expert Opin Investig Drugs 2010;19:919-30
   PubMed Web of Science ®Google Scholar
• Bogani C, Bartalucci N, Martinelli S, et al. mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms. PLoS One 2013;8:e54826
   PubMed Web of Science ®Google Scholar
• Guglielmelli P, Barosi G, Rambaldi A, et al. Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis. Blood 2011;118:2069-76
   PubMed Web of Science ®Google Scholar
• Barosi G, Bordessoule D, Briere J, et al. Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET). Blood 2005;106:2849-53
   PubMed Web of Science ®Google Scholar
• Tefferi A, Barosi G, Mesa RA, et al. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for myelofibrosis research and treatment (IWG-MRT). Blood 2006;108:1497-503
   PubMed Web of Science ®Google Scholar
• Sun SY, Rosenberg LM, Wang X, et al. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 2005;65:7052-8
   PubMed Web of Science ®Google Scholar
• Shi Y, Yan H, Frost P, et al. Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade. Mol Cancer Ther 2005;4:1533-40
   PubMed Web of Science ®Google Scholar
• Xue Q, Hopkins B, Perruzzi C, et al. Palomid 529, a novel small-molecule drug, is a TORC1/TORC2 inhibitor that reduces tumor growth, tumor angiogenesis, and vascular permeability. Cancer Res 2008;68:9551-7
   PubMed Web of Science ®Google Scholar
• Syed F, Sherris D, Paus R, et al. Keloid disease can be inhibited by antagonizing excessive mTOR signaling with a novel dual TORC1/2 inhibitor. Am J Pathol 2012;181:1642-58
   PubMed Web of Science ®Google Scholar
• Feldman ME, Apsel B, Uotila A, et al. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol 2009;7:e38
   PubMed Web of Science ®Google Scholar
• Hoang B, Frost P, Shi Y, et al. Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor. Blood 2010;116:4560-8
   PubMed Web of Science ®Google Scholar
• Ono A, Oike R, Okuhashi Y, et al. Comparative effects of PP242 and rapamycin on mTOR signalling and NOTCH signalling in leukemia cells. Anticancer Res 2013;33:809-13
   PubMed Web of Science ®Google Scholar
• Hoang B, Benavides A, Shi Y, et al. The PP242 mammalian target of rapamycin (mTOR) inhibitor activates extracellular signal-regulated kinase (ERK) in multiple myeloma cells via a target of rapamycin complex 1 (TORC1)/eukaryotic translation initiation factor 4E (eIF-4E)/RAF pathway and activation is a mechanism of resistance. J Biol Chem 2012;287:21796-805
   PubMed Web of Science ®Google Scholar
• Apsel B, Blair JA, Gonzalez B, et al. Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol 2008;4:691-9
   PubMed Web of Science ®Google Scholar
• Lee MS, Cha EY, Sul JY, et al. Chrysophanic acid blocks proliferation of colon cancer cells by inhibiting EGFR/mTOR pathway. Phytother Res 2011;25:833-7
   PubMed Web of Science ®Google Scholar
• Yu K, Toral-Barza L, Shi C, et al. Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin. Cancer Res 2009;69:6232-40
   PubMed Web of Science ®Google Scholar
• Cassell A, Freilino ML, Lee J, et al. Targeting TORC1/2 enhances sensitivity to EGFR inhibitors in head and neck cancer preclinical models. Neoplasia 2012;14:1005-14
   PubMed Web of Science ®Google Scholar
• Vakana E, Sassano A, Platanias LC. Induction of autophagy by dual mTORC1-mTORC2 inhibition in BCR-ABL-expressing leukemic cells. Autophagy 2010;6:966-7
   PubMed Web of Science ®Google Scholar
• Ding H, McDonald JS, Yun S, et al. Farnesyltransferase inhibitor tipifarnib inhibits Rheb prenylation and stabilizes Bax in acute myelogenous leukemia cells. Haematologica 2014;99(1):60-9
   PubMed Web of Science ®Google Scholar
• End DW, Smets G, Todd AV, et al. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res 2001;61:131-7
   PubMed Web of Science ®Google Scholar
• Lancet JE, Gojo I, Gotlib J, et al. A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia. Blood 2007;109:1387-94
   PubMed Web of Science ®Google Scholar
• Harousseau JL, Martinelli G, Jedrzejczak WW, et al. A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older. Blood 2009;114:1166-73
   PubMed Web of Science ®Google Scholar
• Witzig TE, Tang H, Micallef IN, et al. Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas. Blood 2011;118:4882-9
   PubMed Web of Science ®Google Scholar
• Mesa RA, Tefferi A, Gray LA, et al. In vitro antiproliferative activity of the farnesyltransferase inhibitor R115777 in hematopoietic progenitors from patients with myelofibrosis with myeloid metaplasia. Leukemia 2003;17:849-55
   PubMed Web of Science ®Google Scholar
• Mesa RA, Camoriano JK, Geyer SM, et al. A phase II trial of tipifarnib in myelofibrosis: primary, post-polycythemia vera and post-essential thrombocythemia. Leukemia 2007;21:1964-70
   PubMed Web of Science ®Google Scholar
• Wang JC, Chen C, Dumlao T, et al. Enhanced histone deacetylase enzyme activity in primary myelofibrosis. Leuk Lymphoma 2008;49:2321-7
   PubMed Web of Science ®Google Scholar
• Skov V, Larsen TS, Thomassen M, et al. Increased gene expression of histone deacetylases in patients with Philadelphia-negative chronic myeloproliferative neoplasms. Leuk Lymphoma 2011;53:123-9
   PubMed Web of Science ®Google Scholar
• Batshaw ML, MacArthur RB, Tuchman M. Alternative pathway therapy for urea cycle disorders: twenty years later. J Pediatr 2001;138:S46-54; discussion S-5
   PubMed Web of Science ®Google Scholar
• Dover GJ, Brusilow S, Charache S. Induction of fetal hemoglobin production in subjects with sickle cell anemia by oral sodium phenylbutyrate. Blood 1994;84:339-43
   PubMed Web of Science ®Google Scholar
• Rubenstein RC, Zeitlin PL. A pilot clinical trial of oral sodium 4-phenylbutyrate (Buphenyl) in deltaF508-homozygous cystic fibrosis patients: partial restoration of nasal epithelial CFTR function. Am J Respir Crit Care Med 1998;157:484-90
   PubMed Web of Science ®Google Scholar
• Samid D, Shack S, Sherman LT. Phenylacetate: a novel nontoxic inducer of tumor cell differentiation. Cancer Res 1992;52:1988-92
   PubMed Web of Science ®Google Scholar
• Carducci MA, Gilbert J, Bowling MK, et al. A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule. Clin Cancer Res 2001;7:3047-55
   PubMed Web of Science ®Google Scholar
• Inoue Y, Suzuki T, Takimoto M, et al. Treatment with valproic acid for myelofibrosis with myeloid metaplasia. Ann Hematol 2005;84:833-4
   PubMed Web of Science ®Google Scholar
• Drummond DC, Noble CO, Kirpotin DB, et al. Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol 2005;45:495-528
   PubMed Web of Science ®Google Scholar
• Lee J. Clinical efficacy of vorinostat in a patient with essential thrombocytosis and subsequent myelofibrosis. Ann Hematol 2009;88:699-700
   PubMed Web of Science ®Google Scholar
• Andersen CL, McMullin MF, Ejerblad E, et al. A phase II study of vorinostat (MK-0683) in patients with polycythaemia vera and essential thrombocythaemia. Br J Haematol 2013;162:498-508
   PubMed Web of Science ®Google Scholar
• Prince HM, Bishton MJ, Harrison SJ. Clinical studies of histone deacetylase inhibitors. Clin Cancer Res 2009;15:3958-69
   PubMed Web of Science ®Google Scholar
• Wang Y, Fiskus W, Chong DG, et al. Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells. Blood 2009;114:5024-33
   PubMed Web of Science ®Google Scholar
• Mascarenhas J, Lu M, Li T, et al. A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera/essential thrombocythaemia myelofibrosis (post-PV/ET MF). Br J Haematol 2013;161:68-75
   PubMed Web of Science ®Google Scholar
• Harrison CN, Kiladjian JJ, Heidel FH, et al. A phase 1B, dose-finding study of ruxolitinib plus panobinostat in patients with primary myelofibrosis (MF), post-polycythemia vera MF (PPV-MF) or post-essential thrombocythemia MF [abstract s0364]. Haematologia (Budap) 2012;97(s1):146
   Google Scholar
• Leoni F, Fossati G, Lewis EC, et al. The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo. Mol Med 2005;11:1-15
   PubMed Web of Science ®Google Scholar
• Galli M, Salmoiraghi S, Golay J, et al. A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma. Ann Hematol 2010;89:185-90
   PubMed Web of Science ®Google Scholar
• Barbetti V, Gozzini A, Rovida E, et al. Selective anti-leukaemic activity of low-dose histone deacetylase inhibitor ITF2357 on AML1/ETO-positive cells. Oncogene 2008;27:1767-78
   PubMed Web of Science ®Google Scholar
• Rambaldi A, Dellacasa CM, Finazzi G, et al. A pilot study of the Histone-Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. Br J Haematol 2010;150:446-55
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Kantarjian H, Estrov Z, et al. Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis. Leuk Res 2012;36:1124-7
   PubMed Web of Science ®Google Scholar
• Baylin SB, Herman JG, Graff JR, et al. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res 1998;72:141-96
   PubMed Web of Science ®Google Scholar
• Wang JC, Chen W, Nallusamy S, et al. Hypermethylation of the P15INK4b and P16INK4a in agnogenic myeloid metaplasia (AMM) and AMM in leukaemic transformation. Br J Haematol 2002;116:582-6
   PubMed Web of Science ®Google Scholar
• Kumagai T, Tefferi A, Jones L, Koeffler HP. Methylation analysis of the cell cycle control genes in myelofibrosis with myeloid metaplasia. Leuk Res 2005;29:511-15
   PubMed Web of Science ®Google Scholar
• Danilov AV, Relias V, Feeney DM, Miller KB. Decitabine is an effective treatment of idiopathic myelofibrosis. Br J Haematol 2009;145:131-2
   PubMed Web of Science ®Google Scholar
• Mascarenhas J, Navada S, Malone A, et al. Therapeutic options for patients with myelofibrosis in blast phase. Leuk Res 2010;34:1246-9
   PubMed Web of Science ®Google Scholar
• Liu Y, Tabarroki A, Billings S, et al. Successful use of very low dose subcutaneous decitabine to treat high-risk myelofibrosis with Sweet syndrome that was refractory to 5-azacitidine. Leuk Lymphoma 2014;55:447-9
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Tong W, Kantarjian H, et al. A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis. Leukemia 2008;22:965-70
   PubMed Web of Science ®Google Scholar
• Mesa RA, Verstovsek S, Rivera C, et al. 5-Azacitidine has limited therapeutic activity in myelofibrosis. Leukemia 2009;23:180-2
   PubMed Web of Science ®Google Scholar
• Thepot S, Itzykson R, Seegers V, et al. Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM). Blood 2010;116:3735-42
   PubMed Web of Science ®Google Scholar
• Bock O, Serinsoz E, Schlue J, Kreipe H. Different expression levels of the telomerase catalytic subunit hTERT in myeloproliferative and myelodysplastic diseases. Leuk Res 2004;28:457-60
   PubMed Web of Science ®Google Scholar
• Florena AM, Tripodo C, Di Bernardo A, et al. Different immunophenotypical apoptotic profiles characterise megakaryocytes of essential thrombocythaemia and primary myelofibrosis. J Clin Pathol 2009;62:331-8
   PubMed Web of Science ®Google Scholar
• Baerlocher G, Leibundgut E, Spitzer G, et al. Imetelsat: a novel approach with robust hematologic and molecular responses in a phase 2 study in patients with essential thrombocythemia (ET) who are refractory or intolerant to prior therapy. Haematologia (Budap) 2013;98(s1):457
   Google Scholar
• Begna K, Laborde RR, Patnaik MM, et al. Imetelstat, a telomerase inhibitor, induces morphologic and molecular remissions in myelofibrosis and reversal of bone marrow fibrosis. Blood 2013;122:662
   Web of Science ®Google Scholar
• Irvine DA, Copland M. Targeting hedgehog in hematologic malignancy. Blood 2012;119:2196-204
   PubMed Web of Science ®Google Scholar
• Zingariello M, Martelli F, Ciaffoni F, et al. Characterization of the TGF-beta1 signaling abnormalities in the Gata1low mouse model of myelofibrosis. Blood 2013;121:3345-63
   PubMed Web of Science ®Google Scholar
• Keller MD, Rampal RK, Shank K, et al. Improved efficacy Of combination of JAK2 and hedgehog inhibitors in myelofibrosis. Blood 2013;122:666
   PubMed Web of Science ®Google Scholar
• Molnar J, Fong KS, He QP, et al. Structural and functional diversity of lysyl oxidase and the LOX-like proteins. Biochim Biophys Acta 2003;1647:220-4
   PubMed Web of Science ®Google Scholar
• Tadmor T, Bejar J, Attias D, et al. The expression of lysyl-oxidase gene family members in myeloproliferative neoplasms. Am J Hematol 2013;88:355-8
   PubMed Web of Science ®Google Scholar
• Zaffryar-Eilot S, Marshall D, Voloshin T, et al. Lysyl oxidase-like-2 promotes tumour angiogenesis and is a potential therapeutic target in angiogenic tumours. Carcinogenesis 2013;34:2370-9
   PubMed Web of Science ®Google Scholar
• Papadantonakis N, Matsuura S, Ravid K. Megakaryocyte pathology and bone marrow fibrosis: the lysyl oxidase connection. Blood 2012;120:1774-81
   PubMed Web of Science ®Google Scholar
• Akiri G, Sabo E, Dafni H, et al. Lysyl oxidase-related protein-1 promotes tumor fibrosis and tumor progression in vivo. Cancer Res 2003;63:1657-66
   PubMed Web of Science ®Google Scholar
• Rodriguez HM, Vaysberg M, Mikels A, et al. Modulation of lysyl oxidase-like 2 enzymatic activity by an allosteric antibody inhibitor. J Biol Chem 2010;285:20964-74
   PubMed Web of Science ®Google Scholar
• Barry-Hamilton V, Spangler R, Marshall D, et al. Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment. Nat Med 2010;16:1009-17
   PubMed Web of Science ®Google Scholar
• Talal AH, Feron-Rigidon M, Madere J, et al. Simtuzumab, an antifibrotic monoclonal antibody against lysyl oxidase-like 2 (LOXL2) enzyme, appears safe and well tolerated in patients with liver disease of diverse etiology. J Hepatol 2013;58:s532
   Web of Science ®Google Scholar
• Boveri E, Passamonti F, Rumi E, et al. Bone marrow microvessel density in chronic myeloproliferative disorders: a study of 115 patients with clinicopathological and molecular correlations. Br J Haematol 2008;140:162-8
   PubMed Web of Science ®Google Scholar
• Mesa RA, Hanson CA, Rajkumar SV, et al. Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia. Blood 2000;96:3374-80
   PubMed Web of Science ®Google Scholar
• Alonci A, Allegra A, Bellomo G, et al. Evaluation of circulating endothelial cells, VEGF and VEGFR2 serum levels in patients with chronic myeloproliferative diseases. Hematol Oncol 2008;26:235-9
   PubMed Web of Science ®Google Scholar
• Mesa RA, Silver RT, Verstovsek S, et al. Single agent bevacizumab for myelofibrosis: results of the Myeloproliferative Disorders Research Consortium Trial. Haematologica 2013;98:1421-3
   PubMed Web of Science ®Google Scholar
• Nikolaidis I, Makrilia N, Xyla V, et al. Bevacizumab may be active in myelofibrosis. Cancer Invest 2010;28:111-12
   PubMed Web of Science ®Google Scholar
• Galimberti S, Canestaro M, Ciancia E, et al. Bortezomib is able to reduce angiogenesis in half of patients affected by idiopathic myelofibrosis: an ex vivo study. Leuk Res 2008;32:1324-5
   PubMed Web of Science ®Google Scholar
• Mesa RA, Verstovsek S, Rivera C, et al. Bortezomib therapy in myelofibrosis: a phase II clinical trial. Leukemia 2008;22:1636-8
   PubMed Web of Science ®Google Scholar
• Barosi G, Gattoni E, Guglielmelli P, et al. Phase I/II study of single-agent bortezomib for the treatment of patients with myelofibrosis. Clinical and biological effects of proteasome inhibition. Am J Hematol 2010;85:616-19
   PubMed Web of Science ®Google Scholar
• Apostolidou E, Kantarjian H, Thomas D, et al. Phase II study of sunitinib in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Clin Lymphoma Myeloma Leuk 2010;10:281-4
   PubMed Web of Science ®Google Scholar
• Vannucchi AM, Bianchi L, Paoletti F, et al. A pathobiologic pathway linking thrombopoietin, GATA-1, and TGF-beta1 in the development of myelofibrosis. Blood 2005;105:3493-501
   PubMed Web of Science ®Google Scholar
• Mascarenhas J, Li T, Sandy L, et al. Anti-transforming growth factor-beta therapy in patients with myelofibrosis. Leuk Lymphoma 2014;55:450-2
   PubMed Web of Science ®Google Scholar
• Hagop K, Kiladjian J-J, Gotlib J, et al. A pooled overall survival analysis of the COMFORT studies: 2 randomized phase 3 trials of ruxolitinib for the treatment of myelofibrosis. Blood 2013;122:2820
   Web of Science ®Google Scholar
• Tefferi A, Cervantes F, Mesa R, et al. Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European LeukemiaNet (ELN) consensus report. Blood 2013;122(8):1395-8
   PubMed Web of Science ®Google Scholar